HOME
ABOUT IAC
CONTACT
A-Z INDEX
DONATE
SHOP
SUBSCRIBE
Immunization Action Coalition
IAC Home
|
Ask the Experts
|
Polio

Ask the Experts

Polio

Make a Donation Ask the Experts Home
Administering Vaccines
Billing and Reimbursement
Combination Vaccines
Diphtheria
Documenting Vaccination
Hib
Hepatitis A
Hepatitis B
HPV
Influenza
MMR
Meningococcal ACWY
Meningococcal B
Pertussis
Pneumococcal
Polio
Precautions and Contraindications
Rabies
Rotavirus
Scheduling Vaccines
Storage and Handling
Tetanus
Travel Vaccines
Vaccine Recommendations
Vaccine Safety
Varicella (chickenpox)
Zoster (shingles)
 
Polio
What is the routine schedule for giving IPV (IPOL, Sanofi Pasteur) to children?
In the U.S., all infants and children should receive 4 doses of IPV at ages 2, 4, 6–18 months, and 4–6 years. The first dose may be given as early as 6 weeks of age. The final dose should be administered at 4 years of age or older, regardless of the number of previous doses, and should be given 6 months or more after the previous dose. A fourth dose in the routine IPV series is not necessary if the third dose was given at 4 years of age or older and 6 months or more after the previous dose.
Infants and children traveling to areas where there has been wild or vaccine-derived poliovirus circulation in the last 12 months should be vaccinated according to the routine schedule (see wwwnc.cdc.gov/travel/news-announcements/polio-guidance-new-requirements for details). If the routine series cannot be administered within the recommended intervals before protection is needed, an accelerated schedule can be used: 1) the first dose should be given to infants 6 weeks of age and older, 2) the second and third doses should be administered at 4 weeks or more after the previous doses, and 3) the minimum interval between the third and fourth doses is 6 months. If the age-appropriate series is not completed before departure, the remaining IPV doses to complete a full series should be administered when feasible, at the intervals recommended for the accelerated schedule. If doses are needed while residing in the affected country, the polio vaccine that is available (IPV or oral polio vaccine) may be administered.
What is the schedule for older children who have not completed their IPV series?
The schedule for polio vaccination for unvaccinated or under-vaccinated older children through age 17 years is 2 doses of IPV separated by 4–8 weeks, and a third dose 6–12 months after the second dose. If an accelerated schedule is needed, the child should receive two doses separated by at least 4 weeks and a third (final) dose given at least 6 months after the second dose. Polio vaccine is not routinely administered to persons 18 years of age and older.
Should adults get vaccinated against polio?
Routine polio vaccination of U.S. residents 18 years of age and older—including those working in healthcare or in healthcare-related training—is not recommended. Polio vaccination is recommended for all travelers to countries with wild poliovirus (WPV) or vaccine-derived poliovirus (VDPV) circulation. Countries are considered to have WPV or VDPV circulation if they have evidence during the previous 12 months of ongoing endemic circulation (WPV only), a polio outbreak, or environmental evidence (through sewage sampling) of WPV or VDPV circulation. For additional information on countries with WPV or VDPV circulation and vaccine recommendations, consult the travel notices on the CDC Travelers' Health website (www.cdc.gov/travel) or the weekly update of reported WPV and VDPV cases at the Global Polio Eradication Initiative website (www.polioeradication.org/Dataandmonitoring/Poliothisweek.aspx).
Adults who are traveling to areas where WPV or VDPV is actively circulating and who are unvaccinated, incompletely vaccinated, or whose vaccination status is unknown should receive a series of 3 doses: 2 doses of IPV administered at an interval of 4–8 weeks; a third dose should be administered 6–12 months after the second. If 3 doses of IPV cannot be administered within the recommended intervals before protection is needed, the following alternatives are recommended:
  • If more than 8 weeks is available before protection is needed, 3 doses of IPV should be administered at least 4 weeks apart.
  • If less than 8 weeks but more than 4 weeks is available before protection is needed, 2 doses of IPV should be administered at least 4 weeks apart.
  • If less than 4 weeks is available before protection is needed, a single dose of IPV is recommended.
If less than 3 doses are administered, the remaining IPV doses to complete a 3-dose series should be administered when feasible, at the intervals recommended above, if the person remains at increased risk for poliovirus exposure.
If an adult at risk previously received only one or two documented doses of polio vaccine (either OPV or IPV), he or she should receive the remaining dose(s) of IPV, regardless of the interval since the last dose. It is not necessary to restart the vaccination series.
Adults who have completed a routine series of polio vaccine are considered to have lifelong immunity to poliomyelitis, but data on duration of immunity are lacking. As a precaution, adults 18 years of age or older who are traveling to areas where WPV or VDPV is actively circulating and who have received a routine series with either IPV or OPV in childhood should receive another dose of IPV before departure. For adults, available data do not indicate the need for more than a single lifetime booster dose with IPV.
We have an adult who was diagnosed with polio as a child with some residual effects. This adult will be traveling overseas and the CDC travel website recommends a dose of polio vaccine. Should he be vaccinated with polio vaccine even though he had polio in the past?
Immunity to one of the serotypes of polio does not produce significant immunity to the other serotypes. A history of having recovered from polio disease should not be considered evidence of immunity to polio. It would be appropriate to vaccinate this adult if he will be traveling to an area for which polio vaccination is recommended.
Please describe the CDC recommendations for polio vaccination for infants, children, and adults traveling to and from countries affected by wild or vaccine-derived poliovirus.
These recommendations evolve as the polio eradication program progresses. Please see wwwnc.cdc.gov/travel/news-announcements/polio-guidance-new-requirements for the most current guidance.
A 4-year-old's vaccine records show that she had 4 IPVs, given at 2m, 4m, 6m, and age 2. Should she have a booster dose?
Yes. In June, 2009, ACIP updated its recommendations to clarify that an additional dose must be given at age 4-6 years, even if the child previously received 4 doses (either as IPV or as part of a combination vaccine containing IPV).
We frequently see children (mostly from certain foreign countries) who have received 6 or more doses of polio vaccine, all administered before 4 years of age. How do we handle this when assessing the child’s immunization history?
It is common practice in many developing countries to administer oral polio vaccine to children during both routine visits and periodic vaccination campaigns, so a child’s record may indicate more than 4 doses. Depending on the timing, some of these doses may not be valid according to the U.S. immunization schedule. Polio vaccine given outside the United States is valid if written documentation indicates that all doses were given after 6 weeks of age and the vaccine received was IPV or trivalent OPV (tOPV).
If the history is of a complete series of IPV, at least one dose should be administered on or after 4 years of age and at least 6 months after the previous dose. If a complete series cannot be identified that meets these criteria, then the child should receive as many doses of IPV as needed to complete the U.S. recommended schedule.
How do I determine if doses of polio vaccine administered outside the United States were trivalent OPV?
Use the date of administration to make a presumptive determination of what type of OPV was received. Only trivalent doses count as valid for the U.S. polio vaccination schedule.
Trivalent OPV was used throughout the world prior to April 2016. In April 2016, all countries using OPV switched to bivalent OPV (bOPV). In addition, some countries also use monovalent OPV (mOPV) during special vaccination campaigns. Doses recorded as bOPV or mOPV, or doses given during a vaccination campaign (which may be included on the record), do not count as valid doses for the U.S. polio vaccination schedule.
If the record indicates OPV, and the dose was given prior to April 1, 2016, it can be counted as a valid tOPV dose. If the dose was administered on or after April 1, 2016, it should not be counted as a valid dose for the U.S. polio vaccination schedule because it was bivalent or monovalent vaccine rather than trivalent.
Persons younger than 18 years of age with doses of OPV that do not count towards the U.S. vaccination requirements should receive IPV to complete the schedule according to the U.S. polio immunization schedule. See www.cdc.gov/mmwr/volumes/66/wr/pdfs/mm6601a6.pdf for more information on this issue.
We occasionally encounter teen-agers who received 4 doses of IPV before their fourth birthday. Should we recommend a 5th dose of IPV for these children?
Generally, no. ACIP revised its recommendation for IPV in June 2009 to include a dose at 4 through 6 years regardless of the number of doses prior to age 4 years. However, ACIP did not recommend retroactive application of the new minimum age rule for the fourth dose. For children receiving their fourth dose prior to August 7, 2009, four doses separated by at least 4 weeks is sufficient, unless the teenager is traveling to a polio-endemic area. But you might want to check with your state immunization registry manager to see what they accept/expect. Contact information for state immunization managers can be found at www.immunize.org/coordinators.
If an immigrant infant has a record of 1 or 2 doses of OPV in their country of origin how many more doses of IPV should be given?
Polio vaccine given outside the United States is valid if written documentation indicates that all doses were given after 6 weeks of age and the vaccine received was IPV or trivalent OPV (tOPV). See the previous question for details on assessment of OPV doses by the date of administration.
If both tOPV and IPV were or will be administered as part of a series, the total number of doses needed to complete the series is the same as that recommended for the U.S. IPV schedule. If the child is younger than 4 years of age a total of 4 doses of polio vaccine are recommended. If the child is currently 4 years of age or older, a total of 3 doses completes the series. A minimum interval of 4 weeks should separate doses in the series, with the final dose administered on or after the fourth birthday and at least 6 months after the previous dose. If only tOPV was administered, and all doses were given before 4 years of age, 1 dose of IPV should be given at 4 years of age or older, at least 6 months after the last tOPV dose.
Our 23-year-old patient has been accepted to a physician assistant program that requires polio vaccine for all students. She has 2 documented doses of oral polio vaccine (OPV) as a child, then recently had a dose of inactivated polio vaccine (IPV). How many more doses of IPV does she need to complete the series and on what schedule?
U.S. residents 18 years and older generally do not require polio vaccination. However, in this case the person is required to have evidence of vaccination for a medical training program. People who receive a mixed series of OPV and IPV should receive a total of either 3 or 4 doses depending on the age at the time of the last dose. In this case the recent dose of IPV can be counted as the third and final dose dose in the series. The minimum interval between the next-to-last and last doses in the polio vaccination series is 6 months and the last dose should be at age 4 years or older.
Is it true that IPV can be given either SC or IM?
Yes.
What is the risk of serious reactions following IPV?
There are no severe reactions known to occur following IPV.
 
This page was updated on July 25, 2018.
This page was reviewed on January 16, 2018.
 
- Guide to immunize.org -
A-Z INDEX
ABOUT IAC
ACIP RECOMMENDATIONS
ADDITIONAL RESOURCES
ADULT VACCINATION
ADULT VACCINATION GUIDE
ASK THE EXPERTS
Combination Vaccines
Diphtheria
Hepatitis A
Hepatitis B
Vaccine Storage and Handling
>> view all
BILLING & CODING
BIRTH DOSE GUIDEBOOK
CALENDAR OF EVENTS
CDC INFORMATION
CDC SCHEDULES
CLINIC TOOLS
Administering Vaccines
Adult Vaccination
Documenting Vaccination
Scheduling Vaccination
Screening for Contraindications
Storage & Handling
Vaccine Recommendations
>> view all
COALITIONS
CONTRIBUTE TO IAC
DEAR COLLEAGUE LETTER
HPV VACCINE
DEAR COLLEAGUE LETTER
MCV4 DOSE #2
DISEASES & VACCINES
Diphtheria
Hepatitis A
Hepatitis B
Influenza
Varicella
>> view all
DONATE TO IAC
EMAIL NEWS SERVICES
EDUCATIONAL MATERIALS
EXEMPTIONS
FAQs
FAVORITES (WEB SECTIONS)
FDA PRODUCT APPROVALS
GIVE BIRTH TO THE END OF
HEP B
HANDOUTS FOR PATIENTS &
STAFF
Administering Vaccines
Adult Vaccination
Documenting Vaccinations
Managing Vaccine Reactions
Parent Handouts
Patient Schedules
Questions & Answers
Recommendations
Screening Checklists
Standing Orders
Storage & Handling
Talking with Parents
Temperature Logs
Top Handouts
Translations
Vaccine Index
>> view all
HEPATITIS B BIRTH DOSE
HONOR ROLLS
HepB Birth Dose
Influenza Vaccination for HCP
IAC EXPRESS
IMAGES
IMMUNIZATION TECHNIQUES
DVD
LAMINATED SCHEDULES
LAWS AND MANDATES
MANUFACTURERS
NATIONAL ADULT & INFLUENZA IMMUNIZATION SUMMIT
NEWS & INFORMATION
OFFICIAL RELEASES
ACIP
CDC
FDA
>> view all
PACKAGE INSERTS
PARTNERS
PHARMACISTS
PHOTOS
POWERPOINT SLIDE SETS
PRESS ROOM
PROTECT NEWBORNS
FROM HEP B
PUBLICATIONS
IAC Express
Vaccinating Adults:
   A Step-by-Step Guide
REGISTRIES
RESOURCE DIRECTORY
SHOP IAC
Immunization Techniques DVD
Laminated Schedules
Patient Record Cards
>> view all
SITE MAP
SLIDE SETS
STANDING ORDERS TEMPLATES
STATE INFORMATION
State Websites
State Laws
State Immunization Managers
>> view all
SUBSCRIBE
SUPPORT IAC
TECHNICALLY SPEAKING
TIMELINE FOR VACCINES
TRANSLATE FOR IAC
TRANSLATIONS OF VISs
TRAVEL (INTERNATIONAL)
UNPROTECTED PEOPLE REPORTS
Chickenpox
Diphtheria
Hepatitis A
Hepatitis B
>> view all
VACCINATING ADULTS: A STEP-BY-STEP GUIDE
VACCINE CONCERNS
Adjuvants & Ingredients
Alternative Medicine
Autism
Importance of Vaccination
>> view all
VACCINE INFORMATION STATEMENTS
Translations
Vaccine Index
>> view all
VACCINE MANUFACTURERS
VACCINE POLICY & LICENSURE
ACIP
FDA
WHO
>> view all
VACCINE SAFETY
VACCINE TIMELINE
VACCINES & DISEASES
VIDEOS (VIDEO OF THE WEEK)
WHAT'S NEW OR UPDATED AT IAC
Handouts
VISs and Translations
Web Sections
>> view all
 
Immunization Action Coalition  •  2550 University Avenue West  •  Suite 415 North  •  Saint Paul, Minnesota  •  55114
tel 651-647-9009  •  fax 651-647-9131
 
 
 
This website is supported in part by a cooperative agreement from the National Center for Immunization and Respiratory Diseases (Grant No. 6NH23IP22550) at the Centers for Disease Control and Prevention (CDC) in Atlanta, GA. The website content is the sole responsibility of IAC and does not necessarily represent the official views of CDC.